6 results on '"Sook Kwan Brown"'
Search Results
2. Global update on the susceptibilities of human influenza viruses to neuraminidase inhibitors and the cap-dependent endonuclease inhibitor baloxavir, 2018-2020
- Author
-
Elena A. Govorkova, Emi Takashita, Rod S. Daniels, Seiichiro Fujisaki, Lance D. Presser, Mira C. Patel, Weijuan Huang, Angie Lackenby, Ha T. Nguyen, Dmitriy Pereyaslov, Aine Rattigan, Sook Kwan Brown, Magdi Samaan, Kanta Subbarao, Sun Wong, Dayan Wang, Richard J. Webby, Hui-Ling Yen, Wenqing Zhang, Adam Meijer, and Larisa V. Gubareva
- Subjects
Pharmacology ,Dibenzothiepins ,Pyridones ,Triazines ,Morpholines ,Neuraminidase ,Infectious Disease ,Neuraminidase inhibitor ,Endonucleases ,Antiviral Agents ,Influenza ,Reduced susceptibility ,Influenza B virus ,Influenza A Virus, H1N1 Subtype ,Oseltamivir ,Ecology,Evolution & Ethology ,Amino Acid Substitution ,Virology ,Baloxavir ,Polymerase inhibitor ,Drug Resistance, Viral ,Influenza, Human ,Humans ,Antiviral ,Enzyme Inhibitors - Abstract
Global analysis of the susceptibility of influenza viruses to neuraminidase (NA) inhibitors (NAIs) and the polymerase acidic (PA) inhibitor (PAI) baloxavir was conducted by five World Health Organization Collaborating Centres for Reference and Research on Influenza during two periods (May 2018-May 2019 and May 2019-May 2020). Combined phenotypic and NA sequence-based analysis revealed that the global frequency of viruses displaying reduced or highly reduced inhibition (RI or HRI) or potential to show RI/HRI by NAIs remained low, 0.5% (165/35045) and 0.6% (159/26010) for the 2018-2019 and 2019-2020 periods, respectively. The most common amino acid substitution was NA-H275Y (N1 numbering) conferring HRI by oseltamivir and peramivir in A(H1N1)pdm09 viruses. Combined phenotypic and PA sequence-based analysis showed that the global frequency of viruses showing reduced susceptibility to baloxavir or carrying substitutions associated with reduced susceptibility was low, 0.5% (72/15906) and 0.1% (18/15692) for the 2018-2019 and 2019-2020 periods, respectively. Most (n = 61) of these viruses had I38���T/F/M/S/L/V PA amino acid substitutions. In Japan, where baloxavir use was highest, the rate was 4.5% (41/919) in the 2018-2019 period and most of the viruses (n = 32) had PA-I38T. Zoonotic viruses isolated from humans (n = 32) in different countries did not contain substitutions in NA associated with NAI RI/HRI phenotypes. One A(H5N6) virus had a dual substitution PA-I38V + PA-E199G, which may reduce susceptibility to baloxavir. Therefore, NAIs and baloxavir remain appropriate choices for the treatment of influenza virus infections, but close monitoring of antiviral susceptibility is warranted.
- Published
- 2021
3. Characterization of influenza B viruses with reduced susceptibility to influenza neuraminidase inhibitors
- Author
-
Sook Kwan Brown, Yeu-Yang Tseng, Ammar Aziz, Mariana Baz, and Ian G. Barr
- Subjects
Pharmacology ,Influenza B virus ,Oseltamivir ,Virology ,Drug Resistance, Viral ,Influenza, Human ,Humans ,Neuraminidase ,Zanamivir ,Enzyme Inhibitors ,Antiviral Agents - Abstract
A total of 3425 influenza B viruses collected from the Asia-Pacific region were tested against the four registered neuraminidase inhibitors (NAIs) (oseltamivir carboxylate, zanamivir, peramivir and laninamivir) as part of the routine surveillance work at the WHO Collaborating Centre for Research and Reference on Influenza, Melbourne between 2016 and 2020. Forty-five influenza B viruses with reduced susceptibility to one or more NAIs were identified. While the majority of these had neuraminidase (NA) mutations that were known to confer NAIs resistance, fifteen had NA mutations that had not been confirmed as being responsible for reduced NAIs susceptibility. Eleven of these NA mutations of concern were investigated using reverse genetics (RG) techniques to verify that these mutations were the cause of the reduced NAI susceptibility. All mutations were introduced separately into the NA of B/Brisbane/27/2016 (a B Victoria-lineage virus) or B/Yamanashi/166/98 (a B Yamagata-lineage virus) and the effects of these were analysed by an in vitro NAI assay. The T146K substitution in the NA of B Victoria and Yamagata-lineages resulted in a large increase in the IC
- Published
- 2021
4. Report on influenza viruses received and tested by the Melbourne WHO Collaborating Centre for Reference and Research on Influenza in 2019
- Author
-
Heidi Peck, Jean Moselen, Sook Kwan Brown, Megan Triantafilou, Hilda Lau, Michel Grau, Ian G Barr, and Vivian KY Leung
- Subjects
viruses ,Influenza A Virus, H3N2 Subtype ,Australia ,virus diseases ,General Medicine ,World Health Organization ,respiratory tract diseases ,Influenza A Virus, H1N1 Subtype ,Influenza Vaccines ,Influenza, Human ,Animals ,Humans ,Female ,Chickens ,Phylogeny - Abstract
As part of its role in the World Health Organization’s (WHO) Global Influenza Surveillance and Response System (GISRS), the WHO Collaborating Centre for Reference and Research on Influenza in Melbourne received a record total of 9,266 human influenza positive samples during 2019. Viruses were analysed for their antigenic, genetic and antiviral susceptibility properties. Selected viruses were propagated in qualified cells or embryonated hen’s eggs for potential use in seasonal influenza virus vaccines. In 2019, influenza A(H3N2) viruses predominated over influenza A(H1N1)pdm09 and B viruses, accounting for a total of 51% of all viruses analysed. The majority of A(H1N1)pdm09, A(H3N2) and influenza B viruses analysed at the Centre were found to be antigenically similar to the respective WHO recommended vaccine strains for the Southern Hemisphere in 2019. However, phylogenetic analysis indicated that a significant proportion of circulating A(H3N2) viruses had undergone genetic drift relative to the WHO recommended vaccine strain for 2019. Of 5,301 samples tested for susceptibility to the neuraminidase inhibitors oseltamivir and zanamivir, four A(H1N1)pdm09 viruses showed highly reduced inhibition with oseltamivir, one A(H1N1)pdm09 virus showed highly reduced inhibition with zanamivir and three B/Victoria viruses showed highly reduced inhibition with zanamivir.
- Published
- 2021
5. Report on influenza viruses received and tested by the Melbourne WHO Collaborating Centre for Reference and Research on Influenza during 2020–2021
- Author
-
Genevieve O’Neill, Ammar Aziz, Miku Kuba, Sook Kwan Brown, Hilda Lau, Sally Soppe, Mariana Baz, Heidi Peck, Yi-Mo Deng, Kanta Subbarao, and Ian G Barr
- Subjects
Influenza A Virus, H3N2 Subtype ,Australia ,Neuraminidase ,General Medicine ,World Health Organization ,Antiviral Agents ,Influenza B virus ,Influenza A Virus, H1N1 Subtype ,Oseltamivir ,Influenza Vaccines ,Drug Resistance, Viral ,Influenza, Human ,Humans ,Zanamivir - Abstract
As part of its role in the World Health Organization’s (WHO) Global Influenza Surveillance and Response System (GISRS), the WHO Collaborating Centre for Reference and Research on Influenza in Melbourne received a total of 2,393 human influenza positive samples between 1 January 2020 and 31 December 2021 (2020: n = 2,021 samples; 2021: n = 372 samples). Viruses were analysed for their antigenic, genetic and antiviral susceptibility properties. Selected viruses were propagated in qualified cells or embryonated hen’s eggs for potential use in seasonal influenza virus vaccines. During 2020–2021, influenza A viruses (A(H1N1)pdm09 in 2020 and A(H3N2) in 2021) predominated over influenza B viruses. In 2020, the majority of A(H1N1)pdm09, A(H3N2) and influenza B viruses analysed at the Centre were found to be antigenically similar to the respective WHO recommended vaccine strains for the southern hemisphere in 2020. In 2021, the majority of A(H1N1)pdm09 and A(H3N2) viruses were found to be antigenically distinct relative to the WHO recommended vaccine strains for the southern hemisphere in 2021. Of the influenza B viruses analysed at the Centre, 46.7% were found to be antigenically distinct to the respective WHO recommended vaccine strains. Of 1,538 samples tested for susceptibility to the neuraminidase inhibitors oseltamivir and zanamivir (in 2020, n = 1,374; in 2021, n = 164), two A(H1N1)pdm09 viruses showed highly reduced inhibition against oseltamivir, and one A(H1N1)pdm09 virus showed highly reduced inhibition against zanamivir. All of these samples were received in 2020.
- Published
- 2020
6. Report on influenza viruses received and tested by the Melbourne WHO Collaborating Centre for Reference and Research on Influenza in 2018
- Author
-
Cleve Rynehart, Olivia Price, Sally Soppe, Natalie Spirason, Sook Kwan Brown, Ian G. Barr, Manisha Patel, Michelle K Chow, Heidi Peck, and Angela Todd
- Subjects
0301 basic medicine ,Oseltamivir ,medicine.medical_specialty ,viruses ,030106 microbiology ,Drug resistance ,medicine.disease_cause ,World Health Organization ,Antiviral Agents ,Virus ,03 medical and health sciences ,chemistry.chemical_compound ,0302 clinical medicine ,Zanamivir ,Antigen ,Molecular genetics ,Drug Resistance, Viral ,Influenza, Human ,Influenza A virus ,medicine ,Animals ,Humans ,030212 general & internal medicine ,Antigens, Viral ,Phylogeny ,biology ,Australia ,virus diseases ,General Medicine ,Virology ,Influenza B virus ,chemistry ,Influenza Vaccines ,biology.protein ,Neuraminidase ,Chickens ,medicine.drug - Abstract
As part of its role in the World Health Organization’s (WHO) Global Influenza Surveillance and Response System (GISRS), the WHO Collaborating Centre for Reference and Research on Influenza in Melbourne received a total of 3993 human influenza-positive samples during 2018. Viruses were analysed for their antigenic, genetic and antiviral susceptibility properties. Selected viruses were propagated in qualified cells or hens’ eggs for use as potential seasonal influenza vaccine virus candidates. In 2018, influenza A(H1)pdm09 viruses predominated over influenza A(H3) and B viruses, accounting for a total of 53% of all viruses analysed. The majority of A(H1)pdm09, A(H3) and influenza B viruses analysed at the Centre were found to be antigenically similar to the respective WHO-recommended vaccine strains for the Southern Hemisphere in 2018. However, phylogenetic analysis indicated that a significant proportion of circulating A(H3) viruses had undergone genetic drift relative to the WHO-recommended vaccine strain for 2018. Of 2864 samples tested for susceptibility to the neuraminidase inhibitors oseltamivir and zanamivir, three A(H1)pdm09 viruses showed highly reduced inhibition by oseltamivir, while one B/Victoria virus showed highly reduced inhibition by both oseltamivir and zanamivir.
- Published
- 2020
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.